Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]CTI BioPharma"
Count: 63
Selected: 0
NCT03165734A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT05657613Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects
NCT05552183Study to Evaluate the Safety, Tolerability, and PK of Pacritinib
NCT01632436Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment
NCT01638442Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects
NCT00106600Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)
NCT02823171To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects
NCT02808455Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects
NCT02807207To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects
NCT02807116Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects
NCT04404361PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
NCT04884191Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
NCT01321541Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
NCT02055781Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
NCT00269828A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
NCT00576225CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
NCT00551239Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
NCT00004026CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy
NCT00017433Arsenic Trioxide in Treating Patients With Multiple Myeloma
NCT00577161Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
NCT00551733Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00054210Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00054197Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00054184Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
NCT00020969Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
NCT00017069Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
NCT01773187Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
NCT02765724Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects
NCT00088530BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
NCT02807051To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects
NCT02800889Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
NCT02807077PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects
NCT02803762Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib
NCT00268853A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin
NCT00060684Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
NCT00060671Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
NCT00291785Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer
NCT00291837CT-2106 for the Second Line Treatment of Ovarian Cancer
NCT00069901Phase II CT-2103/Carboplatin in Ovarian Cancer
NCT00384111Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
NCT00660218A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer
NCT02584777A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
NCT01491841IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
NCT02323607Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations
NCT02410551Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
NCT02469415Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
NCT02452346Study of Clinical Efficacy and Safety of Tosedostat in MDS
NCT02564536Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
NCT01227408Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer
NCT02277093Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer